【24h】

The unusual gradient elution for reversed phase HPLC of a strong chelator as an active drug substance.

机译:强螯合剂作为活性药物的反相HPLC的异常梯度洗脱。

获取原文
获取原文并翻译 | 示例
           

摘要

The new approach to drug development, especially for cardiovascular and brain diseases, brought to synthesis of new lipophillic derivatives of strong calcium chelator BAPTA - DP-b99 and DP-109. Due to their chelating ability, these compounds require metal-free stationary phases, and their high hydrophobicity resulted in unusually steep gradient elution. Novel HPLC methods for analysis of these two compounds were developed. Purospher RP-C18, 5 microm, 125 x 3.0 mm and XTerra RP18, 3.5 microm, 100 x 4.6 mm columns with a steep gradient from: 1% acetic acid to acetonitrile were used for DP-b99, and Hypersil HyPurity C4, 5 microm, 100 x 4.6 mm column with a steep gradient from 1% Acetic acid to 5% THF in methanol -- for DP-109. Versatile detection techniques could be used with these LC procedures. The methods appeared to be sensitive, selective, reproducible and stability indicating. They could be easily upgraded to bioanalytical methods with LC-MS technique.
机译:药物开发的新方法,特别是针对心血管疾病和脑疾病的新方法,合成了强钙螯合剂BAPTA的新型亲脂衍生物-DP-b99和DP-109。由于它们的螯合能力,这些化合物需要不含金属的固定相,并且它们的高疏水性导致异常陡峭的梯度洗脱。开发了用于分析这两种化合物的新型HPLC方法。 Pur-pher RP-C18、5微米,125 x 3.0毫米和XTerra RP18、3.5微米,100 x 4.6毫米色谱柱(从1%乙酸到乙腈的陡峭梯度)用于DP-b99,Hypersil HyPurity C4 5微米100 x 4.6毫米色谱柱,在1%乙酸到5%THF的甲醇溶液中具有陡峭的梯度-适用于DP-109。这些LC程序可以使用多种检测技术。该方法似乎是灵敏,选择性,可重现和稳定的。使用LC-MS技术可以轻松将其升级为生物分析方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号